Coherus Oncology (CHRS) vs Innate Pharma S.A. (IPHA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Innate Pharma S.A. (IPHA) has outperformed Coherus Oncology (CHRS) over the past year, losing 26.4% versus a loss of 39.2%. Over five years, IPHA leads with a -74.8% price change compared with -93.7% for CHRS. Innate Pharma S.A. is the larger company by market cap ($165.3 million vs $165.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CHRS | IPHA |
|---|---|---|
| Share price | $1.07 | $1.48 |
| Market cap | $165.32M | $165.32M |
| 1-day change | +5.94% | -2.63% |
| YTD return | -24.65% | -15.43% |
| 1-year return | -39.20% | -26.37% |
| 5-year return | -93.71% | -74.79% |
| EPS (TTM) | $-1.25 | $-0.59 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.62 | $2.71 |
| 52-week low | $0.974 | $1.17 |
| Distance from 52-week high | -59.10% | -45.39% |
| Analyst consensus | none | none |
| Avg. price target upside | +624.30% | +350.68% |
| Average volume | 1.16M | 156.96K |
| Shares outstanding | 154.50M | 111.70M |
| Employees | 144 | 120 |
| Sector | Health Care | Healthcare |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IPHA has outperformed CHRS by 12.8 percentage points over the past year.
- The two companies sit in different sectors: Coherus Oncology in Health Care and Innate Pharma S.A. in Healthcare.
About Coherus Oncology
CHRS stock →Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 144 employees
About Innate Pharma S.A.
IPHA stock →Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally.
Healthcare · Biotechnology · 120 employees
CHRS vs IPHA FAQ
Which is bigger, Coherus Oncology or Innate Pharma S.A.?
Innate Pharma S.A. (IPHA) is larger, with a market capitalization of $165.32M compared with $165.32M for Coherus Oncology (CHRS).
Which stock has performed better over the past year, CHRS or IPHA?
IPHA returned -26.37% over the past 12 months, compared with -39.20% for CHRS (price return, excluding dividends). Past performance does not predict future results.
Are Coherus Oncology and Innate Pharma S.A. in the same industry?
No. Coherus Oncology is in the Health Care sector, while Innate Pharma S.A. is in Healthcare.